Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01798706
Registration number
NCT01798706
Ethics application status
Date submitted
22/02/2013
Date registered
26/02/2013
Date last updated
18/04/2017
Titles & IDs
Public title
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Query!
Scientific title
A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen
Query!
Secondary ID [1]
0
0
2012-003292-19
Query!
Secondary ID [2]
0
0
EFC12703
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
GetGoal-O
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Lixisenatide (AVE0010)
Treatment: Drugs - Placebo
Treatment: Drugs - Antidiabetic background therapy
Experimental: Lixisenatide - Lixisenatide 10 mcg once daily (QD) for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
Placebo comparator: Placebo - Placebo (matched to lixisenatide) QD for 24 Weeks.
Treatment: Drugs: Lixisenatide (AVE0010)
Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning
Route of administration: Subcutaneous injection
Treatment: Drugs: Placebo
Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning
Route of administration: Subcutaneous injection
Treatment: Drugs: Antidiabetic background therapy
Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide \>10 mg, gliclazide \>160 mg), meglitinides (except repaglinide \>6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Absolute Change in HbA1c From Baseline to Week 24
Query!
Assessment method [1]
0
0
Change in HbA1c was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using last on-treatment observation carried forward (LOCF). On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. Here, number of participants analyzed=participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.
Query!
Timepoint [1]
0
0
Baseline, Week 24
Query!
Secondary outcome [1]
0
0
Change in 2-Hour PPG From Baseline to Week 24
Query!
Assessment method [1]
0
0
The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug.
Query!
Timepoint [1]
0
0
Baseline, Week 24
Query!
Secondary outcome [2]
0
0
Change in Average 7-point SMPG Profiles From Baseline to Week 24
Query!
Assessment method [2]
0
0
Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime three times in a week before baseline, before visit Week 12 and before visit week 26 and the average value across the profiles performed in the week a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to the day of last dose of study drug.
Query!
Timepoint [2]
0
0
Baseline, Week 24
Query!
Secondary outcome [3]
0
0
Change in Body Weight From Baseline to Week 24
Query!
Assessment method [3]
0
0
Change in body weight was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug.
Query!
Timepoint [3]
0
0
Baseline, Week 24
Query!
Secondary outcome [4]
0
0
Change in FPG From Baseline to Week 24
Query!
Assessment method [4]
0
0
Change in FPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to 1 day after the last dose of study drug.
Query!
Timepoint [4]
0
0
Baseline, Week 24
Query!
Secondary outcome [5]
0
0
Percentage of Participants Requiring Rescue Therapy During 24 Week Treatment Period
Query!
Assessment method [5]
0
0
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG \>270 mg/dL (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \>200 mg/dL (11.1 mmol/L) or HbA1c \>9%.
Query!
Timepoint [5]
0
0
Baseline up to Week 24
Query!
Secondary outcome [6]
0
0
Change in Plasma Glucose Excursions From Baseline to Week 24
Query!
Assessment method [6]
0
0
Plasma glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the liquid standardized breakfast meal test, before study drug administration. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug.
Query!
Timepoint [6]
0
0
Baseline, Week 24
Query!
Secondary outcome [7]
0
0
Change in Total Daily Basal Insulin Dose From Baseline to Week 24 (in Participants Who Took Basal Insulin as Background Therapy)
Query!
Assessment method [7]
0
0
Change in basal insulin dose was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to the day of last dose of study drug.
Query!
Timepoint [7]
0
0
Baseline, Week 24
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Symptomatic and Severe Symptomatic Hypoglycemia
Query!
Assessment method [8]
0
0
Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the participant required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.
Query!
Timepoint [8]
0
0
First dose of study drug up to 3 days after the last dose administration (maximum of 171 days)
Query!
Secondary outcome [9]
0
0
Percentage of Participants With HbA1c Reduction >0.5% at Week 24 and Did Not Experienced Documented (Plasma Glucose <60 mg/dL) Symptomatic Hypoglycemia
Query!
Assessment method [9]
0
0
The on-treatment period for HbA1c assessment was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. The on-treatment period for symptomatic hypoglycemia assessment was defined as the time from the first dose of study drug up to 1 day after the last dose of study drug.
Query!
Timepoint [9]
0
0
Week 24
Query!
Secondary outcome [10]
0
0
Percentage of Participants With Gastrointestinal Disorders
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Up to Day 171
Query!
Eligibility
Key inclusion criteria
Inclusion criteria :
* Older participants, aged 70 years and above, with T2DM inadequately controlled on their current anti-diabetic pharmaceutical treatment regimen.
* Signed written informed consent.
Query!
Minimum age
70
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
* At screening HbA1c =7.0% or >10% (Acknowledging that the threshold of 7% may not be appropriate for all older participants and that this was the responsibility of the investigator to include the participant based on an individual evaluation of the expected benefits of better glycemic control versus risk of hypoglycemia).
* At screening participants on both basal insulin and sulfonylurea or basal insulin and meglitinides.
* At screening FPG >250 mg/dL (>13.9 mmol/L).
* Type 1 diabetes mellitus or history of ketoacidosis within one year prior to the screening visit.
* Type 2 diabetes mellitus diagnosed less than 1 year prior to screening.
* Anti-diabetic treatment not at a stable regimen or initiated within the last 3 months prior to screening.
* Treatment within the 3 months preceding the screening with other anti-diabetic agent than allowed background therapy. Allowed therapy includes metformin, sulfonylurea (except glibenclamide >10mg, gliclazide >160mg), meglitinides (except repaglinide >6mg), pioglitazone and basal insulin and should follow local product circulars and labeling restrictions for the study population.
* Participants who had been on an approved or an investigational Glucagon-like peptide 1 (GLP-1) medication (exenatide, liraglutide, lixisenatide or others).
* History of severe hypoglycemia associated with symptoms unawareness or results in unconsciousness/coma/seizure in the 6 months prior to screening.
* BMI <22 or >40 kg/m^2.
* Malnutrition assessed clinically by the investigator or any sub-investigator and by Mini-Nutritional Assessment-Short Form (MNA-SF) score <12 in countries (the judgment of the investigator prevails on questionnaires scores).
* Cognitive disorder and dementia assessed clinically by the investigator or any sub investigator and by Mini Mental State Examination (MMSE) score <24 (the judgment of the investigator prevails on questionnaires scores), or any neurologic disorder that affected the participant's ability to participate in the study.
* Participant who had a glomerular filtration rate (eGFR) (using the Modification of Diet in Renal Disease (MDRD) formula <30ml/min/1.73m^2).
* Participant with severe or uncontrolled disease, or any clinically significant abnormality identified on physical examination or investigational clinical procedure that, in the judgment of the investigator or any sub-investigator, would preclude safe completion of the study or constrains efficacy assessment.
* Laboratory findings at the time of screening:
* Amylase and/or lipase: >3 times the upper limit of the normal (ULN) laboratory range
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times ULN
* Calcitonin >20 pg/mL (5.9 pmol/L).
* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (i.e. worsening) and not controlled (i.e. prolonged nausea and vomiting) gastroesophageal reflux disease within 6 months prior to screening.
* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease.
* Personal or immediate family history of medullary thyroid cancer or genetic conditions that predisposed to medullary thyroid cancer (e.g., multiple endocrine neoplasia syndromes).
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
350
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Investigational Site Number 036002 - Box Hill
Query!
Recruitment hospital [2]
0
0
Investigational Site Number 036006 - Brookvale
Query!
Recruitment hospital [3]
0
0
Investigational Site Number 036004 - Camperdown
Query!
Recruitment hospital [4]
0
0
Investigational Site Number 036005 - Gosford
Query!
Recruitment hospital [5]
0
0
Investigational Site Number 036001 - Heidelberg
Query!
Recruitment hospital [6]
0
0
Investigational Site Number 036003 - Parkville
Query!
Recruitment postcode(s) [1]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [2]
0
0
2100 - Brookvale
Query!
Recruitment postcode(s) [3]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [4]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [5]
0
0
3081 - Heidelberg
Query!
Recruitment postcode(s) [6]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Iowa
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Maryland
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Mississippi
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Nebraska
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Dakota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Utah
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Wisconsin
Query!
Country [12]
0
0
Bulgaria
Query!
State/province [12]
0
0
Plovdiv
Query!
Country [13]
0
0
Bulgaria
Query!
State/province [13]
0
0
Sofia
Query!
Country [14]
0
0
Bulgaria
Query!
State/province [14]
0
0
Stara Zagora
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Varna
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Hamilton
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
London
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Sherbrooke
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
St-Romuald
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Vancouver
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Westmount
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Winnipeg
Query!
Country [23]
0
0
Denmark
Query!
State/province [23]
0
0
Esbjerg
Query!
Country [24]
0
0
Denmark
Query!
State/province [24]
0
0
København Nv
Query!
Country [25]
0
0
Denmark
Query!
State/province [25]
0
0
København S
Query!
Country [26]
0
0
Denmark
Query!
State/province [26]
0
0
Slagelse
Query!
Country [27]
0
0
Denmark
Query!
State/province [27]
0
0
Svendborg
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Dresden
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Essen
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
München
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Münster
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Pirna
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Pohlheim
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Potsdam
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Saarlouis
Query!
Country [36]
0
0
Norway
Query!
State/province [36]
0
0
Hønefoss
Query!
Country [37]
0
0
Norway
Query!
State/province [37]
0
0
Kongsvinger
Query!
Country [38]
0
0
Norway
Query!
State/province [38]
0
0
Oslo
Query!
Country [39]
0
0
Norway
Query!
State/province [39]
0
0
Stavanger
Query!
Country [40]
0
0
Norway
Query!
State/province [40]
0
0
Trondheim
Query!
Country [41]
0
0
Peru
Query!
State/province [41]
0
0
Arequipa
Query!
Country [42]
0
0
Peru
Query!
State/province [42]
0
0
Lima
Query!
Country [43]
0
0
Peru
Query!
State/province [43]
0
0
Piura
Query!
Country [44]
0
0
Poland
Query!
State/province [44]
0
0
Gdansk
Query!
Country [45]
0
0
Poland
Query!
State/province [45]
0
0
Krakow
Query!
Country [46]
0
0
Poland
Query!
State/province [46]
0
0
Poznan
Query!
Country [47]
0
0
Poland
Query!
State/province [47]
0
0
Ruda Slaska
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Szczecin
Query!
Country [49]
0
0
South Africa
Query!
State/province [49]
0
0
Cape Town
Query!
Country [50]
0
0
South Africa
Query!
State/province [50]
0
0
Somerset West
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Alcira
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Barcelona
Query!
Country [53]
0
0
Spain
Query!
State/province [53]
0
0
Hostalets De Balenyà
Query!
Country [54]
0
0
Spain
Query!
State/province [54]
0
0
Madrid
Query!
Country [55]
0
0
Spain
Query!
State/province [55]
0
0
Sanlúcar De Barrameda
Query!
Country [56]
0
0
Spain
Query!
State/province [56]
0
0
Santiago De Compostela
Query!
Country [57]
0
0
Sweden
Query!
State/province [57]
0
0
Göteborg
Query!
Country [58]
0
0
Sweden
Query!
State/province [58]
0
0
Härnösand
Query!
Country [59]
0
0
Sweden
Query!
State/province [59]
0
0
Lund
Query!
Country [60]
0
0
Sweden
Query!
State/province [60]
0
0
Malmö
Query!
Country [61]
0
0
Sweden
Query!
State/province [61]
0
0
Stockholm
Query!
Country [62]
0
0
United Kingdom
Query!
State/province [62]
0
0
Bexhill-On-Sea
Query!
Country [63]
0
0
United Kingdom
Query!
State/province [63]
0
0
Glasgow
Query!
Country [64]
0
0
United Kingdom
Query!
State/province [64]
0
0
Irvine
Query!
Country [65]
0
0
United Kingdom
Query!
State/province [65]
0
0
Trowbridge
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary objective: - To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by glycosylated hemoglobin (HbA1c) reduction, in older type 2 diabetes participants (T2DM) who are inadequately controlled with their current anti-diabetic treatment regimen. Main secondary objective: - To assess the safety and tolerability of lixisenatide compared to placebo in older T2DM participants (including occurrence of documented (Plasma Glucose PG \< 60 mg/dL) symptomatic hypoglycemia and gastrointestinal side effects). Other secondary objectives: * To assess the effect of lixisenatide compared to placebo after 24-week treatment on: * Fasting plasma glucose (FPG); * During liquid standardized breakfast meal challenge test : 2 hour- Postprandial Plasma Glucose (PPG) and Plasma Glucose Excursion; * 7-point Self-monitored plasma glucose (SMPG) profile; * Body weight; * Change in total daily dose of basal insulin (if taken); * Percentage of participants requiring rescue therapy * Safety and tolerability; * To assess lixisenatide pharmacokinetic profile; * To assess anti-lixisenatide antibody development.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01798706
Query!
Trial related presentations / publications
Meneilly GS, Roy-Duval C, Alawi H, Dailey G, Bellido D, Trescoli C, Manrique Hurtado H, Guo H, Pilorget V, Perfetti R, Simpson H; GetGoal-O Trial Investigators. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial. Diabetes Care. 2017 Apr;40(4):485-493. doi: 10.2337/dc16-2143. Epub 2017 Feb 10.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Meneilly GS, Roy-Duval C, Alawi H, Dailey G, Belli...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT01798706
Download to PDF